Mustang Bio 将来の成長

Future 基準チェック /06

Mustang Bio の収益は、年間 1.9% 減少すると予測されています。EPS は、年間増加すると予測されています75.6%。

主要情報

-1.9%

収益成長率

75.6%

EPS成長率

Biotechs 収益成長	26.8%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 Sep 2024

今後の成長に関する最新情報

Recent updates

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Jun 11

Checking Back In On Mustang Bio

May 26

FDA accepts Mustang Bio's MB-106 application in cancer

May 10

Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

Mar 22

What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Feb 23

業績と収益の成長予測

NasdaqCM:MBIO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	N/A	-23	N/A	N/A	1
12/31/2024	N/A	-20	N/A	N/A	1
9/30/2024	N/A	-23	-17	-17	N/A
6/30/2024	N/A	-32	-27	-27	N/A
3/31/2024	N/A	-40	-37	-37	N/A
12/31/2023	N/A	-52	-50	-49	N/A
9/30/2023	N/A	-63	-58	-58	N/A
6/30/2023	N/A	-72	-63	-61	N/A
3/31/2023	N/A	-74	-68	-67	N/A
12/31/2022	N/A	-78	-68	-65	N/A
9/30/2022	N/A	-78	-69	-64	N/A
6/30/2022	N/A	-76	-64	-60	N/A
3/31/2022	N/A	-71	-61	-54	N/A
12/31/2021	N/A	-66	-59	-54	N/A
9/30/2021	N/A	-67	-54	-48	N/A
6/30/2021	N/A	-63	-53	-47	N/A
3/31/2021	N/A	-63	-47	-43	N/A
12/31/2020	N/A	-60	-42	-37	N/A
9/30/2020	N/A	-56	-42	-37	N/A
6/30/2020	N/A	-53	-40	-36	N/A
3/31/2020	N/A	-49	-41	-37	N/A
12/31/2019	N/A	-46	-37	-34	N/A
9/30/2019	0	-42	-33	-31	N/A
6/30/2019	0	-39	-29	-26	N/A
3/31/2019	N/A	-34	-28	-20	N/A
12/31/2018	N/A	-31	-27	-19	N/A
9/30/2018	0	-34	-26	-18	N/A
6/30/2018	0	-34	N/A	-19	N/A
3/31/2018	N/A	-34	N/A	-16	N/A
12/31/2017	N/A	-31	N/A	-13	N/A
9/30/2017	N/A	-24	N/A	-10	N/A
6/30/2017	N/A	-19	N/A	-6	N/A
3/31/2017	N/A	-15	N/A	-6	N/A
12/31/2016	N/A	-13	N/A	-4	N/A
9/30/2016	N/A	-6	N/A	-3	N/A
6/30/2016	N/A	-5	N/A	-3	N/A
3/31/2016	N/A	-4	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MBIO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MBIO今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MBIO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MBIOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: MBIO来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MBIOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/01/12 13:59
終値	2025/01/10 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Mustang Bio, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。6

アナリスト	機関
Mayank Mamtani	B. Riley Securities, Inc.
Justin Zelin	B. Riley Securities, Inc.
Jonathan Aschoff	B. Riley Wealth

Mustang Bio 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 43% to US$10.00

Price target decreased by 29% to US$13.00

Consensus EPS estimates upgraded to US$5.61 loss

Price target decreased by 35% to US$40.75

Consensus EPS estimates fall by 286%

Price target increased by 20% to US$75.00

Recent updates

Mustang Bio, Inc., Annual General Meeting, Dec 26, 2024

Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

New major risk - Market cap size

New major risk - Financial position

New major risk - Market cap size

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million.

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million.

Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy

New major risk - Shareholder dilution

Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Price target decreased by 43% to US$10.00

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $3.998428 million.

New minor risk - Share price stability

Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)(1)

New major risk - Market cap size

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $10.5 million.

New major risk - Financial position

Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer

Price target decreased by 29% to US$13.00

Mustang Bio, Inc. announced that it has received $4.742942 million in funding

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

uBriGene (Boston) Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Consensus EPS estimates upgraded to US$5.61 loss

Price target decreased by 35% to US$40.75

Consensus EPS estimates fall by 286%

Price target increased by 20% to US$75.00

uBriGene (Boston) Biosciences Inc. entered into asset purchase agreement to acquire Worcester manufacturing facility of Mustang Bio, Inc. for $11 million.

Mustang Bio, Inc. Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Price target decreased to US$5.00

Insufficient new directors

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of Mb-106, A First-In-Class Cd20-Targeted, Autologous Car T Cell Therapy to Treat B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio: This Horse May Gallop Still

Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat Rag1 Severe Combined Immunodeficiency

Mustang Bio, Inc. Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

Mustang Bio Receives Letter from the Listing Qualifications Staff of Nasdaq

Mustang Bio, Inc. Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

Price target decreased to US$7.40

Mustang Bio, Inc. Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Mustang Bio, Inc. Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Mustang Bio: The Market Is Missing This Opportunity

Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Mustang Bio Inc. Announces Updated Interim Phase 1/2 Data for Mb-106, Cd20-Targeted Car T Therapy, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Mustang Bio, Inc. Announces Phase 1 Clinical Trial Combining MB-101 and MB-108 for the Treatment of Glioblastoma

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients

Price target decreased to US$8.40

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Price target decreased to US$9.80

Mustang Bio Announces MB-101 (IL13Ra2-targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies

President recently bought US$251k worth of stock

Mustang Bio, Inc. Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Mustang Bio, Inc.(NasdaqGM:MBIO) dropped from Russell 2500 Growth Index

Mustang Bio (MBIO) EHA Investor Presentations - Slideshow

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Checking Back In On Mustang Bio

Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 to Treat Leptomeningeal Brain Tumors